EDBI Pte Ltd’s Relay Therapeutics RLAY Stock Holding History

EDBI Pte Ltd’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,484	Closed	-$167K	–	24
2022 Q3	$167K	Hold	7,484	–	–	0.18%	21
2022 Q2	$125K	Hold	7,484	–	–	0.12%	20
2022 Q1	$224K	Hold	7,484	–	–	0.15%	18
2021 Q4	$230K	Buy	+7,484	New	+$237K	0.13%	16

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EDBI Pte Ltd's RLAY Position: Q4 2022 in Review

EDBI Pte Ltd sold out of Relay Therapeutics (RLAY) in Q4 2022, closing a stake of 7,484 shares — an estimated $167K sold.

EDBI Pte Ltd first reported a position in RLAY in Q4 2021 and held it in 4 quarters. The position peaked at $230K in Q4 2021. 165 funds tracked by Wall St. Rank hold RLAY as of Q4 2022.

EDBI Pte Ltd reported no remaining Relay Therapeutics position as of Q4 2022 after selling out during the quarter.
EDBI Pte Ltd sold 7,484 Relay Therapeutics shares in Q4 2022, an estimated $167K.
EDBI Pte Ltd first reported a position in Relay Therapeutics in Q4 2021 and held it in 4 quarters.
EDBI Pte Ltd's Relay Therapeutics position peaked at $230K in Q4 2021.
165 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2022.

Based on EDBI Pte Ltd's 13F filing for Q4 2022, filed 30 Jan 2023.